- Careers centre
- MJA Open
- Job Search
- MJA Events
Ensuring safety of the 2011 trivalent influenza vaccine in young children
Christopher C Blyth, Tracy Y Markus, Paul V Effler and Peter C Richmond
Med J Aust 2011; 195 (1): 52.
Christopher C Blyth, Associate Professor1,2,3
Tracy Y Markus, Paediatric Registrar3
Paul V Effler, Medical Coordinator4
Peter C Richmond, Associate Professor1,2,3
Dixon GA, Moore HC, Kelly H, et al. Lessons from the first year of the WAIVE study investigating the protective effect of influenza vaccine against laboratory-confirmed influenza in hospitalised children aged 6–59 months. Influenza Other Respi Viruses 2010; 4: 231-234.
Department of Health and Ageing, Therapeutic Goods Administration. Investigation into febrile reactions in young children following 2010 seasonal trivalent influenza vaccination: status report as at 2 July 2010 (updated 24 September 2010). Canberra: TGA, 2010. http://www.tga.gov.au/safety/alerts-medicine-seasonal-flu-100702.htm#fullreport (accessed May 2011).
Armstrong PK, Dowse GK, Effler PV, et al. Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine. BMJ Open 2011. In press.
Blyth CC, Currie AJ, Wiertsema SP, et al. Trivalent influenza vaccine and febrile adverse events in Australia, 2010: clinical features and potential mechanisms. Vaccine 2011. In press. doi: 10.1016/j.vaccine.2011.05.054.
CSL Biotherapies. Fluvax. Product information, October 2010. http://secure.healthlinks.net.au/content/csl/pi.cfm?product=cspfluva11010 (accessed Apr 2011).
The full contents of this page are only available to subscribers.
Log in to keep reading
* Required information